CAR-armored-cell therapy in solid tumor treatment
Journal of Translational Medicine · 2024-11-28 · 22 (1)
DOI: 10.1186/s12967-024-05903-3 ↗At a glance
Übersichtsarbeit in Journal of Translational Medicine, published online on 2024-11-28. Written by Yan Liu and 7 co-authors. Institution: Navy Medical University, Shanghai, 200433, China. Major MEDLINE topics: Neoplasms, Receptors, Chimeric Antigen. Cited 31 times so far (Crossref); 164 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Over the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a revolutionary immunotherapeutic approach to combat cancer. This therapy constructs a CAR on the surface of T cells through genetic engineering techniques. The CAR is formed from a combination of antibody-derived or ligand-derived domains and T-cell receptor (TCR) domains. This enables T cells to specifically bind to and activate against tumor cells. However, the efficacy of CAR-T cells in solid tumors remains inconclusive due to several challenges such as poor tumor trafficking, infiltration, and the immunosuppressive tumor microenvironment (TME). In response, CAR natural killer (CAR-NK) and CAR macrophages (CAR-M) have been developed as complementary strategies for solid tumors. CAR-NK cells do not require HLA compatibility, demonstrate reduced toxicity, and are thus seen as potential substitutes for CAR-T cells. Furthermore, CAR-M immunotherapy is also being researched and has shown phagocytic capabilities and tumor-antigen presentation. This study discusses the features, advantages, and limitations of CAR-T, CAR-NK, and CAR-M cells in the treatment of solid tumors and suggests prospective solutions for enhancing the efficacy of CAR host-cell-based immunotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Navy Medical University, Shanghai, 200433, China.
- Linyi People's Hospital, Linyi, Shandong, 276000, China.
- National Key Laboratory of Medical Immunology & Institute of Immunology, Naval Medical University, Shanghai, China.
- Navy Medical University, Shanghai, 200433, China. guo918meng@163.com.
- National Key Laboratory of Medical Immunology & Institute of Immunology, Naval Medical University, Shanghai, China. guo918meng@163.com.
- Navy Medical University, Shanghai, 200433, China. luojh@immunol.org.
ORCID profiles: Jianhua Luo
Cite
APA
Liu, Y., Xiao, L., Yang, M., Chen, X., Liu, H., Wang, Q., Guo, M., & Luo, J. (2024). CAR-armored-cell therapy in solid tumor treatment. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05903-3
Vancouver
Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, et al. CAR-armored-cell therapy in solid tumor treatment. Journal of Translational Medicine. 2024;22(1). doi:10.1186/s12967-024-05903-3
BibTeX
@article{Liu2024,
author = {Liu, Yan and Xiao, Lin and Yang, Mingxuan and Chen, Xuemei and Liu, Hongyue and Wang, Quanxing and Guo, Meng and Luo, Jianhua},
title = {CAR-armored-cell therapy in solid tumor treatment},
journal = {Journal of Translational Medicine},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12967-024-05903-3}
}
EUVIMED